Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novo nordisk a/s - insulin human - diabetes mellitus - drogi użati fid-dijabete - trattament tad-dijabete mellitus.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novo nordisk a/s - insulina umana - diabetes mellitus - drogi użati fid-dijabete - trattament tad-dijabete mellitus.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

bayer ag - riociguat - pressjoni għolja, pulmonari - antihypertensives għall-ipertensjoni arterjali pulmonari - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. l-effikaċja ġiet murija fil-pah popolazzjoni inklużi l-etjoloġiji ta idjopatika jew li tintiret-pah jew pah assoċċjata ma'mard tal-connective tissue. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

takeda manufacturing austria ag - octocog alfa - hemofilja a - sustanzi kontra l-emorraġija - trattament u profilassi ta 'fsada f'pazjenti b'emofilja a (nuqqas konġenitali ta' fattur viii). advate ma fihx il-fattur von willebrand fi kwantitajiet farmakoloġiċi effettivi u għaldaqstant mhuwiex indikat fil-mard ta ' von willebrand.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

n.v. organon - desloratadine, pseudophedrine sulfate - rinite allerġika staġjonali - preparazzjonijiet imnieħer - trattament sintomatiku ta 'rinite allerġika staġjonali meta jkun akkumpanjat minn konġestjoni nażali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

n.v. organon - desloratadine - rhinitis, allergic, perennial; urticaria; rhinitis, allergic, seasonal - anti-istaminiċi għall-użu sistemiku, - aerius huwa indikat għas-serħan mis-sintomi assoċjati ma': rinite allerġika;urtikarja.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

teva b.v. - salmeterol, fluticasone propionate - pulmonary disease, chronic obstructive; asthma - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - airexar spiromax huwa indikat għall-użu fl-adulti li għandhom 18-il sena 'l fuq biss. asthmaairexar spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist. mard pulmonari ostruttiv kroniku (copd)airexar spiromax huwa indikat għall-kura sintomatika ta ' pazjenti b'copd, bil-fev1.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi b.v. - laronidase - mucopolysaccharidosis i - oħra tal-passaġġ alimentari u tal-metaboliżmu-prodotti, - aldurazyme hu indikat għal enżimi fuq żmien twil terapija tas-sostituzzjoni f'pazjenti b'dijanjosi kkonfermata ta ' mucopolysaccharidosis i (mps i; alfa-l-iduronidase defiċjenza) biex jikkura l-nonneurological manifestazzjonijiet tal-marda.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

immedica pharma ab - sodium phenylbutyrate - ornithine carbamoyltransferase deficiency disease; citrullinemia; carbamoyl-phosphate synthase i deficiency disease - oħra tal-passaġġ alimentari u tal-metaboliżmu-prodotti, - ammonaps hu indikat bħala terapija aġġuntiva fit-kroniku tal-ġestjoni tal-urea disturbi fiċ-ċiklu, li jinvolvi defiċjenzi tal-carbamylphosphate synthetase, ornithine transcarbamylase orargininosuccinate synthetase. huwa indikat fil-pazjenti kollha b'neonatal-onset presentation (tlesti l-enżima n-nuqqasijiet li jidhru fl-ewwel 28 ġurnata tal-ħajja). huwa indikat ukoll f'pazjenti bil-marda li ħarġet tard(nuqqasijiet parzjali fl-enżimi, li jidhru wara l-ewwel xahar tal-ħajja) li għandhom storja ta ' enċefalopatija iperammonemika.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

eli lilly nederland b.v. - duloxetine - neuropatiji dijabetiċi - psychoanaleptics, - trattament ta 'uġigħ newropatiku periferali dijabetiku. ariclaim huwa indikat fl-adulti.